We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

1 hedge funds and large institutions have $13K invested in Alexion Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 11 (0)

0% more capital invested

Capital invested by funds: $13K → $13K ($0)

Holders
1
Holders Change
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ALXN Hedge Fund Activity: Q2 2022 in Review

1 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2022, worth a combined $13K — unchanged from a quarter earlier.

Fund positioning in ALXN was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Alexion Pharmaceuticals (ALXN) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $13K of Alexion Pharmaceuticals stock for Q2 2022, unchanged quarter-over-quarter.
  • 0 funds opened new Alexion Pharmaceuticals positions in Q2 2022 and 0 closed out.

Based on aggregated 13F filings for Q2 2022.